Precision Medicine Today: Predicting Treatment Response in Patient Subgroups

Carina Stanton is a freelance science journalist based in Denver.

References

1. Curtis JR, Yang S, Chen L, et al. Predicting low disease activity and remission using early treatment response to antitumour necrosis factor therapy in patients with rheumatoid arthritis: exploratory analyses from the TEMPO trial. Ann Rheum Dis. 2012 Feb;71(2):206–212.
2. Montgomery A, Chen S, Homan P, et al. Single cell RNA-sequencing reveals distinct macrophage subsets in the joint with differing ontogenies during steady-state and arthritis [abstract]. Arthritis Rheumatol. 2019;71(suppl 10).
3. Yun H, Chen L, Xie F, et al. Do patients with moderate or high disease activity escalate rheumatoid arthritis therapy according to treat‐to‐target principles? Results from the Rheumatology Informatics System for Effectiveness registry of the American College of Rheumatology. Arthritis Care Res (Hoboken). 2020 Feb;72(2):166–175.
4. Bingham C, Kafka S, Black S, et al. Construct validation of PROMIS short form and profile-29 T-Scores with SF-36 in rheumatoid arthritis patients treated for 1 year: Results from a real world evidence-based study in the United States [abstract]. Arthritis Rheumatol. 2019;71(suppl 10).